Current stock page

Stock Analysis

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis

IDEAYA Biosciences, Inc. (IDYA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

IDYA Stock Analysis Summary

IDEAYA Biosciences, Inc. (IDYA) currently has an AIQ Score of 54/100, indicating a neutral setup. Momentum is the strongest factor at 63/100. Value is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

IDYA at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$31.83
AIQ Score54/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$3.28B
P/E Ratio (TTM)-7.09
Forward P/E—
EPS (Q3 FY2026)-$1.22
Revenue (Q3 FY2026)$10.24M
Dividend Yield (TTM)0.00%
Beta0.94
Volume778.82K
52-week range$26.81-$42.68
RSI 1442.42
50-Day SMA$35.47
200-Day SMA$33.85
Analyst Price Target$48.75
Next EarningsFeb 16, 2027
As of Nov 13, 2026 · Market close

IDYAIDEAYA Biosciences, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$31.83+$0.34 (+1.08%)

Latest quote

  • Momentum
    63
  • Value
    39
  • Quality
    51
  • Risk resilience
    61
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

IDYA Stock Analysis Summary

IDEAYA Biosciences, Inc. (IDYA) currently has an AIQ Score of 54/100, indicating a neutral setup. Momentum is the strongest factor at 63/100. Value is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, IDYA has AIQ Score of 54/100 with Momentum base of 63/100 and fading Value at 39/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (63/100) leads while Value (39/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.08% stock move · IDYA classified in Biotechnology.

Current Evidence

NeutralIDYA is in a neutral AIQ regime; Momentum is the strongest visible factor at 63/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is IDYA Bullish or Bearish Right Now?

IDYA currently has a neutral overall setup. Momentum is the strongest factor at 63/100, while Value is weakest at 39/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Analyst target implies +53.16% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 39/100.
  • - Price is -5.97% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (32 vs 5).

Current Consensus

IDYA's Technical Analysis Consensus is currently Strong Sell, with 5 buy, 9 neutral, and 32 sell votes. IDYA's 14-day RSI is 42.42, which places the stock in a weaker momentum range. IDYA's beta is 0.94, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in IDYA?

The largest recent change in IDYA is Value moving up by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+0.0
Quality
+1.0
Risk
+0.0

What Would Change the IDYA Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

IDYA Decision Framework

Public evidence layers, setup checks, and risk context for IDEAYA Biosciences, Inc..

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis

IDEAYA Biosciences, Inc. has an AIQ Score of 54/100 in a Neutral regime. Momentum is strongest at 63/100. Beta is 0.94, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextIDYA is in a Neutral AIQ regime with score 54/100.
Signal ConflictThe primary conflict is that momentum leads at 63/100 while value lags at 39/100.
Factor EvidenceMomentum 63/100 · Value 39/100 · Quality 51/100 · Risk 61/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Momentum is the strongest factor at 63/100.

TimingWait

Momentum is 63/100 and RSI (14) is 42.4.

Regime fitWait

IDYA is in a Neutral regime at 54/100.

Risk controlWait

Risk factor is 61/100 with beta 0.94 and annual volatility 44.94%.

ConflictWait

Current conflict: momentum leads at 63/100 while value lags at 39/100.

AIQ Score
54/100
Price
$31.83
Beta
0.94
RSI (14)
42.4

IDYA Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

IDYA Fundamentals

IDYA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$10.24M
Net income
-$125.75M
Free cash flow
-$93.75M
View full IDYA fundamental analysis

IDYA Technical Analysis

IDYA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
42.42
Price vs SMA-50
-10.25%
View full IDYA technical analysis

IDYA Stock Catalysts

Track IDYA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 16, 2027
Analyst target
$48.75
News items
5
View IDYA earnings and stock catalysts

IDYA Dividend Analysis

IDYA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View IDYA dividend history and analysis

IDYA Financial Data

IDYA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$10.24M
EPS
-$1.22
Periods
8
View IDYA financials

IDYA Risk Analysis

IDYA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.94
Risk score
61/100
1Y volatility
44.94%
View IDYA risk analysis

IDYA Stock News

IDYA stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read IDYA stock news

IDYA vs Biotechnology Peers

Current peer cohort: IDYA · IMNM · IMVT · INBX · INSM. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
IDYA
Current stock
54/10039/10063/10061/1000.1444.94%Current
IMNM
Immunome, Inc.
48/100—45/10047/1000.4560.72%IDYA vs IMNM
IMVT
Immunovant, Inc.
52/100—61/10052/1000.958.62%IDYA vs IMVT
INBX
Inhibrx Biosciences Inc.
40/100—50/10040/1000.4982.28%IDYA vs INBX
INSM
Insmed Incorporated
57/10055/10061/10049/100-0.4863.12%IDYA vs INSM
Pairwise Compare links: IMNM · IMVT · INBX · INSMIDYA vs IMNMIDYA vs IMVTIDYA vs INBXIDYA vs INSMCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a IDYA stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for IDYA: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-7.09
As of Nov 13, 2026
Revenue growth
-95.07%
Gross margin
100.00%
Current debt / equity
0.03
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$10.24M
Quarter net income
-$125.75M
Quarter free cash flow
-$93.75M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
42.42
MACD
-1.1

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
61/100
Beta
0.94
Annual volatility
44.94%
Max drawdown
-27.85%

IDYA Stock FAQ

What is IDYA stock price today?

IDEAYA Biosciences, Inc.'s current stock price is $31.83. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is IDYA bullish or bearish right now?

IDYA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is IDYA's market cap?

IDYA's market cap is $3.28B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is IDYA's current P/E ratio?

IDYA's current P/E ratio is -7.09 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is IDYA's RSI?

IDYA's 14-day RSI is 42.42 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is IDYA above its 50-day and 200-day moving averages?

IDYA is -10.25% from its 50-day SMA and -5.97% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is IDYA's next earnings date?

IDYA's next earnings date is currently listed as Feb 16, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does IDYA pay a dividend?

IDYA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.